AGL 37.91 Decreased By ▼ -0.11 (-0.29%)
AIRLINK 215.50 Increased By ▲ 18.14 (9.19%)
BOP 9.80 Increased By ▲ 0.26 (2.73%)
CNERGY 6.83 Increased By ▲ 0.92 (15.57%)
DCL 9.18 Increased By ▲ 0.36 (4.08%)
DFML 39.00 Increased By ▲ 3.26 (9.12%)
DGKC 100.80 Increased By ▲ 3.94 (4.07%)
FCCL 36.50 Increased By ▲ 1.25 (3.55%)
FFBL 88.94 Increased By ▲ 6.64 (8.07%)
FFL 14.49 Increased By ▲ 1.32 (10.02%)
HUBC 134.52 Increased By ▲ 6.97 (5.46%)
HUMNL 13.65 Increased By ▲ 0.15 (1.11%)
KEL 5.69 Increased By ▲ 0.37 (6.95%)
KOSM 7.39 Increased By ▲ 0.39 (5.57%)
MLCF 46.00 Increased By ▲ 1.30 (2.91%)
NBP 61.20 Decreased By ▼ -0.22 (-0.36%)
OGDC 233.25 Increased By ▲ 18.58 (8.66%)
PAEL 40.75 Increased By ▲ 1.96 (5.05%)
PIBTL 8.57 Increased By ▲ 0.32 (3.88%)
PPL 203.15 Increased By ▲ 10.07 (5.22%)
PRL 41.15 Increased By ▲ 2.49 (6.44%)
PTC 28.38 Increased By ▲ 2.58 (10%)
SEARL 108.40 Increased By ▲ 4.80 (4.63%)
TELE 8.75 Increased By ▲ 0.45 (5.42%)
TOMCL 36.00 Increased By ▲ 1.00 (2.86%)
TPLP 13.80 Increased By ▲ 0.50 (3.76%)
TREET 24.38 Increased By ▲ 2.22 (10.02%)
TRG 61.15 Increased By ▲ 5.56 (10%)
UNITY 34.47 Increased By ▲ 1.50 (4.55%)
WTL 1.74 Increased By ▲ 0.14 (8.75%)
BR100 12,244 Increased By 517.6 (4.41%)
BR30 38,419 Increased By 2042.6 (5.62%)
KSE100 113,924 Increased By 4411.3 (4.03%)
KSE30 36,044 Increased By 1530.5 (4.43%)

The European Commission has approved Novartis' Entresto drug for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction, the Swiss drugmaker said on Tuesday. Entresto is the first new drug in decades for helping patients whose lives are in danger because their hearts cannot pump blood efficiently. Analysts estimate it could have annual sales of some $5.4 billion by 2020.

Copyright Reuters, 2015

Comments

Comments are closed.